Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Genocea Biosciences Inc (EM) GNCAQ

Healthcare Biotechnology
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (EXPM:GNCAQ)

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

GlobeNewswire May 24, 2022

Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives

GlobeNewswire April 28, 2022

Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022

GlobeNewswire April 8, 2022

Genocea Biosciences to Host Investor Webinar

GlobeNewswire April 4, 2022

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference

GlobeNewswire March 14, 2022

Genocea Provides Fourth Quarter 2021 Corporate Update

GlobeNewswire March 10, 2022

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

GlobeNewswire March 8, 2022

John Lunger, of Adaptimmune, Joins Genocea Biosciences' Board of Directors

GlobeNewswire March 7, 2022

Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast

GlobeNewswire March 3, 2022
View More News ››

Opinion & Analysis (EXPM:GNCAQ)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:GNCAQ)

it does look interesting guys

where did you guys go,who were saying they liked this stock.
coolfooldumbguy - June 5, 2019

you guys missed it

actions speak louder than words
coolfooldumbguy - June 3, 2019

RE:RE:Looks interesting

I’m here with you Joe.... let’s do this
ARNULF - April 27, 2019

RE:Looks interesting

Conference on 28th.  May give it more legs.   
mevani - February 26, 2019

Looks interesting

Lots of insider buying.  Took a starter position here.  See what happens.
mevani - February 20, 2019
View more Bullboard ››

Spirit Blockchain Capital Inc.

Spirit Blockchain Capital Inc.

Spirit Blockchain Capital Inc. operates as a digital asset and blockchain company. It offers holds and invests in a portfolio ...
View More »